Healthcare Analysts and CEO & Chairman Nolan and President Nagendran hold a conference call to discuss Rett Syndrome, the pipeline and company strategy on a conference call to be held on September 15 at 10 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TSHA:
- Largest borrow rate increases among liquid names
- Taysha Gene Therapies files to sell 166.66M shares of common stock for holders
- Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
- Taysha Gene Therapies announces FTD granted by FDA for TSHA-102
- Taysha Gene Therapies price target lowered to $7 from $13 at Canaccord